Get the Stockscreener App
0.42
14.00%
-0.08
Bioaffinity Technologies Inc stock is traded at $0.42, with a volume of 85,359.
It is down -14.00% in the last 24 hours and down -39.45% over the past month.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
See More
Previous Close:
$0.50
Open:
$0.4633
24h Volume:
85,359
Relative Volume:
0.50
Market Cap:
$6.86M
Revenue:
$9.37M
Net Income/Loss:
$-8.45M
P/E Ratio:
-0.5185
EPS:
-0.81
Net Cash Flow:
$-7.27M
1W Performance:
-44.87%
1M Performance:
-39.45%
6M Performance:
-69.06%
1Y Performance:
-79.52%
1-Day Range:
$0.3926
$0.49
1-Week Range:
$0.3926
$0.855
52-Week Range:
$0.3926
$3.62
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
22211 WEST INTERSTATE-10, SAN ANTONIO
Compare BIAF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.42 | 6.86M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
525.74 | 198.19B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
207.72 | 148.92B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
128.25 | 36.52B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
439.88 | 35.63B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
188.27 | 33.12B | 15.41B | 1.37B | 2.11B | 7.50 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Large Drop in Short Interest - Defense World
bioAffinity stock hits 52-week low at $0.55 amid market challenges - Investing.com Canada
BioAffinity Technologies Raises $1.4 Million After Warrant Exercise -February 26, 2025 at 12:59 pm EST - Marketscreener.com
How Will bioAffinity's $1.4M Capital Raise Impact Existing Shareholders? - StockTitan
bioAffinity's $1.4M Cash Injection Comes With 61% Warrant DiscountWhat's the Real Cost? - StockTitan
How bioAffinity's $1.4M Warrant Deal Affects Shareholder Value: Dilution vs. Cash Injection - StockTitan
bioAffinity's $1.4M Cash Infusion Comes at a Cost: Warrant Price Slashed by 61% - StockTitan
Early lung cancer diagnosis saves 52-year-old Indian man’s life - Mugglehead
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation - MSN
bioAffinity Technologies faces Nasdaq delisting over price - MSN
bioAffinity Technologies faces Nasdaq delisting over price By Investing.com - Investing.com Nigeria
British scientists develop lung cancer blood test that gives results in 40 minutes - Mugglehead
The Zacks Analyst Blog Highlights Amazon, Bank of America, Caterpillar, NVE and bioAffinity - Nasdaq
Top Research Reports for Amazon.com, Bank of America & Caterpillar - Nasdaq
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 16.7% – Here’s Why - Defense World
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029 - GlobeNewswire
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
bioAffinity Technologies (BIAF) Stock Price, News & Analysis - MarketBeat
BIOAFFINITY TECHNOLOGIES, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
bioAffinity Technologies secures Australian patent for ‘CyPath Lung’ spit test - Mugglehead
bioAffinity secures Australian patent for lung cancer test - MSN
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic - BioSpace
bioAffinity Technologies stock hits 52-week low at $0.65 - MSN
Biotech company CEO receives pay bump - San Antonio Business Journal
bioAffinity Technologies Increases CEO Maria Zannes’ Annual Base Salary to $300,000 - Defense World
bioAffinity Technologies Adjusts CEO Compensation Package - TipRanks
bioAffinity Technologies CEO receives salary increase - Investing.com
bioAffinity Technologies (NASDAQ:BIAFW) Trading Up 4.7% – Time to Buy? - Defense World
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung - BioSpace
bioAffinity's Breakthrough Lung Cancer Test Shows 92% Accuracy, Could Save Medicare $379M - StockTitan
Enlivex CEO to Showcase Breakthrough Allocetra Cell Therapy on Bloomberg TV Special Feature - StockTitan
**bioAffinity Technologies Reports Results of 2024 Special Meeting** - Defense World
bioAffinity Technologies (NASDAQ:BIAF) Shares Down 2% – Here’s Why - Defense World
bioAffinity Technologies Boosts Sales with CyPath Lung - Yahoo Finance
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 25.7% – Time to Sell? - Defense World
San Antonio biotech company looks to expand in 2025 - The Business Journals
bioAffinity Tech to Showcase Breakthrough Lung Cancer Detection Test in Exclusive Investor Webinar - StockTitan
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19 - Business Wire
Flow Cytometry in Oncology Market is Likely to Increase At - openPR
bioAffinity Technologies stock hits 52-week low at $0.91 By Investing.com - Investing.com UK
William Bauta to Spearhead Product Development at bioAffinity Technologies - MPO-mag
bioAffinity Technologies Set for Continued Expansion in 2025 - BioSpace
BioAffinity Technologies Set for Continued Expansion in 2025 - Marketscreener.com
bioAffinity Technologies Adds Japanese Patent to its IP Portfolio - MPO-mag
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioaffinity Technologies Inc Stock (BIAF) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zannes Timothy P | Secretary, EVP, Gen. Counsel |
Apr 04 '24 |
Option Exercise |
1.16 |
64,848 |
75,224 |
75,155 |
| GIRGENTI STEVEN | Director |
Apr 03 '24 |
Option Exercise |
1.16 |
64,848 |
75,224 |
1,056,606 |
4.07%
2.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):